Patient-Reported Outcomes in Systemic Lupus Erythematosus

Rheumatic Disease Clinics of North America

Volumn 42, Issue 2, 2016, Pages 253-263

  Mahieu, Mary ^a   Yount, Susan ^a   Ramsey Goldman, Rosalind ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Patient reported outcomes (PROs); Quality of life (QoL); Systemic lupus erythematosus (SLE, lupus)

Indexed keywords

CLINICAL DECISION MAKING; CLINICAL RESEARCH; COMORBIDITY; CONSTRUCT VALIDITY; CRITERION RELATED VALIDITY; DOCTOR PATIENT RELATION; EUROQOL 5 DIMENSIONS; HUMAN; INTERNAL CONSISTENCY; LUPUS PATIENT REPORTED OUTCOME; LUPUSQOL; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PATIENT PARTICIPATION; PATIENT REPORTED OUTCOME; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SHORT FORM 20; SHORT FORM 36; SLE QUALITY OF LIFE QUESTIONNAIRE; SLE SPECIFIC QUALITY OF LIFE QUESTIONNAIRE; SYSTEMIC LUPUS ERYTHEMATOSUS; TEST RETEST RELIABILITY; PATHOPHYSIOLOGY; PATIENT-REPORTED OUTCOME; QUESTIONNAIRE;

HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATIENT REPORTED OUTCOME MEASURES; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES;

EID: 84961219225     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2016.01.001     Document Type: Review

References (80)

1. Cervera R., Khamashta M.A., Font J., et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003, 82(5):299-308.
2. Siegel M., Lee S.L. The epidemiology of systemic lupus erythematosus. Semin Arthritis Rheum 1973, 3(1):1-54.
3. Trager J., Ward M.M. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol 2001, 13(5):345-351.
4. Bichile T., Petri M. Prevention and management of co-morbidities in SLE. Presse Med 2014, 43(6 Pt 2):e187-e195.
5. Tessier-Cloutier B., Clarke A.E., Ramsey-Goldman R., et al. Systemic lupus erythematosus and malignancies: a review article. Rheum Dis Clin North Am 2014, 40(3):497-506. viii.
6. Merrill J.T. Treatment of systemic lupus erythematosus: a 2012 update. Bull NYU Hosp Jt Dis 2012, 70(3):172-176.
7. Palagini L., Mosca M., Tani C., et al. Depression and systemic lupus erythematosus: a systematic review. Lupus 2013, 22(5):409-416.
8. Palagini L., Tani C., Mauri M., et al. Sleep disorders and systemic lupus erythematosus. Lupus 2014, 23(2):115-123.
9. Schoenfeld S.R., Kasturi S., Costenbader K.H. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 2013, 43(1):77-95.
10. Wekking E.M. Psychiatric symptoms in systemic lupus erythematosus: an update. Psychosom Med 1993, 55(2):219-228.
11. Bernatsky S., Boivin J.F., Joseph L., et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006, 54(8):2550-2557.
12. Schmeding A., Schneider M. Fatigue, health-related quality of life and other patient-reported outcomes in systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2013, 27(3):363-375.
13. McElhone K., Abbott J., Teh L.S. A review of health related quality of life in systemic lupus erythematosus. Lupus 2006, 15(10):633-643.
14. Feld J., Isenberg D. Why and how should we measure disease activity and damage in lupus?. Presse Med 2014, 43(6 Pt 2):e151-e156.
15. Abu-Shakra M., Mader R., Langevitz P., et al. Quality of life in systemic lupus erythematosus: a controlled study. J Rheumatol 1999, 26(2):306-309.
16. Fortin P.R., Abrahamowicz M., Neville C., et al. Impact of disease activity and cumulative damage on the health of lupus patients. Lupus 1998, 7(2):101-107.
17. Burckhardt C.S., Archenholtz B., Bjelle A. Quality of life of women with systemic lupus erythematosus: a comparison with women with rheumatoid arthritis. J Rheumatol 1993, 20(6):977-981.
18. Wang C., Mayo N.E., Fortin P.R. The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus. J Rheumatol 2001, 28(3):525-532.
19. Hanly J.G. Disease activity, cumulative damage and quality of life in systematic lupus erythematosus: results of a cross-sectional study. Lupus 1997, 6(3):243-247.
20. Thumboo J., Fong K.Y., Chan S.P., et al. A prospective study of factors affecting quality of life in systemic lupus erythematosus. J Rheumatol 2000, 27(6):1414-1420.
21. Pons-Estel G.J., Alarcón G.S., Scofield L., et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010, 39(4):257-268.
22. Neville C., Clarke A.E., Joseph L., et al. Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity. J Rheumatol 2000, 27(3):675-679.
23. Yen J.C., Neville C., Fortin P.R. Discordance between patients and their physicians in the assessment of lupus disease activity: relevance for clinical trials. Lupus 1999, 8(8):660-670.
24. Strand V., Gladman D., Isenberg D., et al. Endpoints: consensus recommendations from OMERACT IV. Outcome measures in rheumatology. Lupus 2000, 9(5):322-327.
25. Tugwell P., Chambers L., Torrance G., et al. The population health impact of arthritis. POHEM workshop group. J Rheumatol 1993, 20(6):1048-1051.
26. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30(6):473-483.
27. Stoll T., Gordon C., Seifert B., et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol 1997, 24(8):1608-1614.
28. Hurst N.P., Jobanputra P., Hunter M., et al. Validity of Euroqol-a generic health status instrument-in patients with rheumatoid arthritis. Economic and health outcomes research group. Br J Rheumatol 1994, 33(7):655-662.
29. Hurst N.P., Kind P., Ruta D., et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997, 36(5):551-559.
30. Touma Z., Gladman D.D., Ibañez D., et al. Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus?. J Rheumatol 2011, 38(9):1898-1905.
31. Devilliers H., Amoura Z., Besancenot J.F., et al. Responsiveness of the 36-item short form health survey and the lupus quality of life questionnaire in SLE. Rheumatology (Oxford) 2015, 54(5):940-949.
32. Strand V., Singh J.A. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs 2010, 70(2):121-145.
33. Kiani A.N., Strand V., Fang H., et al. Predictors of self-reported health-related quality of life in systemic lupus erythematosus. Rheumatology (Oxford) 2013, 52(9):1651-1657.
34. Mok C.C., Ho L.Y., Cheung M.Y., et al. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study. Scand J Rheumatol 2009, 38(2):121-127.
35. Urowitz M., Gladman D.D., Ibañez D., et al. Changes in quality of life in the first 5 years of disease in a multicenter cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2014, 66(9):1374-1379.
36. Strand V., Aranow C., Cardiel M.H., et al. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 2003, 12(9):677-686.
37. Wallace D.J., Stohl W., Furie R.A., et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009, 61(9):1168-1178.
38. Strand V., Levy R.A., Cervera R., et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis 2014, 73(5):838-844.
39. McElhone K., Abbott J., Shelmerdine J., et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum 2007, 57(6):972-979.
40. Jolly M., Pickard A.S., Block J.A., et al. Disease-specific patient reported outcome tools for systemic lupus erythematosus. Semin Arthritis Rheum 2012, 42(1):56-65.
41. Leong K.P., Kong K.O., Thong B.Y., et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology (Oxford) 2005, 44(10):1267-1276.
42. Doward L.C., McKenna S.P., Whalley D., et al. The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. Ann Rheum Dis 2009, 68(2):196-200.
43. Stamm T.A., Bauernfeind B., Coenen M., et al. Concepts important to persons with systemic lupus erythematosus and their coverage by standard measures of disease activity and health status. Arthritis Rheum 2007, 57(7):1287-1295.
44. Kuriya B., Gladman D.D., Ibañez D., et al. Quality of life over time in patients with systemic lupus erythematosus. Arthritis Rheum 2008, 59(2):181-185.
45. Aggarwal R., Wilke C.T., Pickard A.S., et al. Psychometric properties of the EuroQol-5D and short form-6D in patients with systemic lupus erythematosus. J Rheumatol 2009, 36(6):1209-1216.
46. Wang S.L., Wu B., Zhu L.A., et al. Construct and criterion validity of the Euro Qol-5D in patients with systemic lupus erythematosus. PLoS One 2014, 9(6):e98883.
47. Wolfe F., Michaud K., Li T., et al. EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, and fibromyalgia. J Rheumatol 2010, 37(2):296-304.
48. Dua A.B., Aggarwal R., Mikolaitis R.A., et al. Rheumatologists' quality of care for lupus: comparison study between a university and county hospital. Arthritis Care Res (Hoboken) 2012, 64(8):1261-1264.
49. Bexelius C., Wachtmeister K., Skare P., et al. Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports. Lupus 2013, 22(8):793-801.
50. Strand V., Galateanu C., Pushparajah D.S., et al. Limitations of current treatments for systemic lupus erythematosus: a patient and physician survey. Lupus 2013, 22(8):819-826.
51. Bjork M., Dahlström Ö., Wetterö J., et al. Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus. BMC Musculoskelet Disord 2015, 16:188.
52. Cella D., Riley W., Stone A., et al. The Patient Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol 2010, 63(11):1179-1194.
53. Oude Voshaar M.A., ten Klooster P.M., Glas C.A., et al. Calibration of the PROMIS physical function item bank in Dutch patients with rheumatoid arthritis. PLoS One 2014, 9(3):e92367.
54. Fries J.F., Cella D., Rose M., et al. Progress in assessing physical function in arthritis: PROMIS short forms and computerized adaptive testing. J Rheumatol 2009, 36(9):2061-2066.
55. Ow Y.L., Thumboo J., Cella D., et al. Domains of health-related quality of life important and relevant to multiethnic English-speaking Asian systemic lupus erythematosus patients: a focus group study. Arthritis Care Res (Hoboken) 2011, 63(6):899-908.
56. Jones J.T., Nelson S.L., Wootton J., et al. A134: validation of patient reported outcomes measurement information system modules for use in childhood-onset lupus. Arthritis Rheumatol 2014, 66:S176-S177.
57. Ahn G, Chmiel JS, Dunlop DD, et al. Accelerometer physical activity measurements, physical function, fatigue, anxiety, depression, pain, and sleep in adults with systemic lupus erythematosus (SLE): the Activity in Lupus to Energize and Renew (ALTER) study, in 10th International Congress on SLE. Buenos Aires, Argentina, April 18-21, 2013. p. P063.
58. Mahieu M.A., Ahn G.E., Chmiel J.S., et al. Fatigue, patient reported outcomes, and objective measurement of physical activity in systemic lupus erythematosus. Lupus 2016, in press.
59. Rothrock N.E., Hays R.D., Spritzer K., et al. Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient-reported Outcomes Measurement Information System (PROMIS). J Clin Epidemiol 2010, 63(11):1195-1204.
60. Khanna D., Maranian P., Rothrock N., et al. Feasibility and construct validity of PROMIS and "legacy" instruments in an academic scleroderma clinic. Value Health 2012, 15(1):128-134.
61. Broderick J.E., Schneider S., Junghaenel D.U., et al. Validity and reliability of Patient-reported Outcomes Measurement Information System instruments in osteoarthritis. Arthritis Care Res (Hoboken) 2013, 65(10):1625-1633.
62. Jolly M., Pickard A.S., Wilke C., et al. Lupus-specific health outcome measure for US patients: the LupusQoL-US version. Ann Rheum Dis 2010, 69(1):29-33.
63. Gonzalez-Rodriguez V., Peralta-Ramírez M.I., Navarrete-Navarrete N., et al. Adaptation and validation of the Spanish version of a disease-specific quality of life measure in patients with systemic lupus erythematosus: the Lupus quality of life. Med Clin (Barc) 2010, 134(1):13-16. [in Spanish].
64. Yilmaz-Oner S., Oner C., Dogukan F.M., et al. Health-related quality of life assessed by LupusQoL questionnaire and SF-36 in Turkish patients with systemic lupus erythematosus. Clin Rheumatol 2015, [Epub ahead of print].
65. Pamuk O.N., Onat A.M., Donmez S., et al. Validity and reliability of the Lupus QoL index in Turkish systemic lupus erythematosus patients. Lupus 2015, 24(8):816-821.
66. Hosseini N., Bonakdar Z.S., Gholamrezaei A., et al. Linguistic validation of the LupusQoL for the assessment of quality of life in Iranian patients with systemic lupus erythematosus. Int J Rheumatol 2014, 2014:151530.
67. Conti F., Perricone C., Reboldi G., et al. Validation of a disease-specific health-related quality of life measure in adult Italian patients with systemic lupus erythematosus: LupusQoL-IT. Lupus 2014, 23(8):743-751.
68. Devilliers H., Amoura Z., Besancenot J.F., et al. LupusQoL-FR is valid to assess quality of life in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2012, 51(10):1906-1915.
69. Wang S.L., Wu B., Leng L., et al. Validity of LupusQoL-China for the assessment of health related quality of life in Chinese patients with systemic lupus erythematosus. PLoS One 2013, 8(5):e63795.
70. Jolly M., Pickard S.A., Mikolaitis R.A., et al. LupusQoL-US benchmarks for US patients with systemic lupus erythematosus. J Rheumatol 2010, 37(9):1828-1833.
71. McElhone K., Castelino M., Abbott J., et al. The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus. J Rheumatol 2010, 37(11):2273-2279.
72. Gordon C., Isenberg D., Lerstrøm K., et al. The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey. Rheumatology (Oxford) 2013, 52(12):2292-2301.
73. Mirbagher L., Gholamrezaei A., Hosseini N., et al. Sleep quality in women with systemic lupus erythematosus: contributing factors and effects on health-related quality of life. Int J Rheum Dis 2014, [Epub ahead of print].
74. Bourre-Tessier J., Clarke A.E., Mikolaitis-Preuss R.A., et al. Cross-cultural validation of a disease-specific patient-reported outcome measure for systemic lupus erythematosus in Canada. J Rheumatol 2013, 40(8):1327-1333.
75. Navarra S.V., Tanangunan R.M., Mikolaitis-Preuss R.A., et al. Cross-cultural validation of a disease-specific patient-reported outcome measure for lupus in Philippines. Lupus 2013, 22(3):262-267.
76. Bourre-Tessier J., Clarke A.E., Kosinski M., et al. The French-Canadian validation of a disease-specific, patient-reported outcome measure for lupus. Lupus 2014, 23(14):1452-1459.
77. Jolly M., Toloza S., Block J., et al. Spanish LupusPRO: cross-cultural validation study for lupus. Lupus 2013, 22(5):431-436.
78. Kaya A., Goker B., Cura E.S., et al. Turkish lupusPRO: cross-cultural validation study for lupus. Clin Rheumatol 2014, 33(8):1079-1084.
79. Mok C.C., Kosinski M., Ho L.Y., et al. Validation of the LupusPRO in Chinese patients from Hong Kong with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2015, 67(2):297-304.
80. Jolly M., Peters K.F., Mikolaitis R., et al. Body image intervention to improve health outcomes in lupus: a pilot study. J Clin Rheumatol 2014, 20(8):403-410.